Core Viewpoint - Dogwood Therapeutics, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement, positioning the company favorably for future growth and shareholder value enhancement [1][2]. Financial Position - As of the end of Q1 2025, Dogwood Therapeutics reported a strong cash position of $17.5 million with no debt, which supports its operational and strategic initiatives [2]. - The company had previously fallen below the $2.5 million minimum stockholders' equity requirement but has since taken steps to rectify this situation [2][3]. Compliance Actions - The company entered into a Debt Exchange and Cancellation Agreement with Conjoint, Inc., resulting in the cancellation of approximately $19.9 million in debt in exchange for shares of Series A-1 Non-Voting Convertible Preferred Stock [4]. - Additionally, Dogwood Therapeutics raised approximately $4.8 million through a stock purchase agreement with institutional investors [4]. Shareholder Information - As of March 31, 2025, there were 1,911,128 shares of the company's common stock issued and outstanding [5]. Research and Development - Dogwood Therapeutics is focused on developing new medicines for pain and fatigue-related disorders, with a research pipeline that includes a non-opioid analgesic program and an antiviral program [6]. - The lead candidate, Halneuron®, has shown promise in clinical studies for reducing pain related to cancer and chemotherapy-induced neuropathic pain, with interim data from ongoing studies expected in Q4 2025 [6]. - The antiviral program includes IMC-1 and IMC-2, targeting conditions related to dormant herpesvirus reactivation, with IMC-1 set to progress to Phase 3 development for fibromyalgia and IMC-2 advancing to Phase 2b research for Long-COVID [7].
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance